Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Noveris Health Sciences (OP:MYCOF)

0.1308 UNCHANGED
Last Price Updated: 3:20 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Noveris Health Sciences

< Previous 1 2 3 Next >
News headline image
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD ↗
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD? 
Via Talk Markets
News headline image
The Year In Review For Psychedelic Drug Stocks: 2021 ↗
2021 was two different 
Via Talk Markets
News headline image
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD ↗
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index. 
Via Talk Markets
News headline image
Mind Medicine to Study Effect of Time on LSD Microdosing ↗
Mind Medicine (NASDAQ: MNMD), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a... 
Via Benzinga
News headline image
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline ↗
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same... 
Via Talk Markets
Topics Cannabis
News headline image
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November ↗
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance. 
Via Talk Markets
Topics Cannabis
News headline image
Psychedelic Drug Stocks Continued To Decline Last Week ↗
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
News headline image
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders ↗
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) (FSE: 0NF... 
Via Benzinga
News headline image
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November ↗
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
News headline image
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine ↗
Dr. Aaron T. Beck, the father of cognitive therapy, died on Monday at his home in Philadelphia at age 100. Beck&rsq... 
Via Benzinga
Topics Death
News headline image
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD. 
Via Talk Markets
News headline image
Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years ↗
The National Institutes of Health awarded a nearly $4 million grant meant to fund research on psilocybin, the act... 
Via Benzinga
News headline image
Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗
Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month. 
Via Talk Markets
News headline image
September Summary: Cannabis-Based Vs. Psychedelic Compounds-Based Drug Stock Performances ↗
Which index out-performed in September, the Pure-Play Marijuana-Based Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
News headline image
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval ↗
Psychedelics and mycology company Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: 
Via Benzinga
Topics Cannabis
News headline image
Which Psychedelic Stock ETF Is Right For You? ↗
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
News headline image
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics ↗
Last Week In Psychedelics: 
Via Benzinga
News headline image
Cannabis And Psychedelic Drug Stock Performances Were Mixed Last Week ↗
The performance of the psychedelic-focused index components substantially outshone the weed stocks. 
Via Talk Markets
Topics Cannabis
News headline image
Psychedelic Drug Industry Report Card For 2021 ↗
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
News headline image
Magic Mushroom Drug Stock Performances YTD ↗
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
News headline image
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT ↗
On Wednesday, PharmaDrug Inc. (CSE:PHRX) (OTC: 
Via Benzinga
News headline image
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up ↗
Beckley Psytech Closes $80 Million Series B Beckley Psytech announced 
Via Benzinga
News headline image
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation ↗
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) has signe... 
Via Benzinga
News headline image
Which Psychedelic Drug Stock Category Outperformed Last Week ↗
Which has performed best YTD, the Pure-Play Marijuana Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
Topics Cannabis
News headline image
Which Psychedelic Drug Has The Most Commercial Potential? ↗
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
News headline image
Marijuana Vs. Mushroom Psychedelic Drug Stocks: A Current & YTD Performance Comparison ↗
We identify the performance of the top 8 clinical-stage psychedelic companies in each of the marijuana and mushroom drug stock categories during the past 5 trading days, July to date, and YTD. 
Via Talk Markets
Topics Cannabis
News headline image
How The Pot And Psychedelic Stocks Performed Last Week And YTD ↗
Approximately 100 clinical-stage marijuana and mushroom/ketamine psychedelic drug stocks now trade on the various North American stock exchanges. 
Via Talk Markets
Topics Cannabis
News headline image
How To Invest In "Magic Mushrooms" (Psychedelics) ↗
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
News headline image
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies ↗
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
News headline image
The 6 Leading Psychedelic Stocks In Drug R&D ↗
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.